Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q1 2023 · 10-Q
Revenue$2.06M$2.06M−29.1% vs Q1 2022 Net Income-$371.00K-$371.00KN/M vs Q1 2022 EPS Diluted$0.00$0.00no prior Q1 2022 on file Gross Profit$487,000−66.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flow-$9,723,000N/M Free Cash Flowderived-$9,924,000N/M Margins · derivedGross margin23.6%−25.9 pt vs Q1 2022
Operating margin-473.1%−425.9 pt vs Q1 2022
Net margin-18.0%+28.3 pt vs Q1 2022
ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end